460 likes | 623 Views
National Estimates from the Drug Abuse Warning Network. CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse & Mental Health Services Administration November 13, 2008 http://DAWNinfo.samhsa.gov. Today's Agenda. No conflicts of interest
E N D
National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse & Mental Health Services Administration November 13, 2008 http://DAWNinfo.samhsa.gov
Today's Agenda • No conflicts of interest • Overview of DAWN • Key findings from 2007 • Nonmedical use of opiates/opioids • 2004-2007 comparisons • Extended- vs. immediate-release oxycodone • Extended- vs. immediate-release morphine 2
DAWN Survey Design • Stratified probability sample of hospitals • Short-term, general, non-Federal hospitals with 24-hour emergency departments (EDs) • National estimates account for: • Sample design • Unit nonresponse • Partial nonresponse in responding hospital 3
Oversample areas (urban)+ Remainder area (urban & rural) National Estimates 4
DAWN Data Collection: Retrospective Review of Medical Records Charts reviewed 10,038,897 ED visits reviewed Cases found 375,031 Drug-related ED visits not reviewed National estimates Source: DAWN, 2007 data, 11/11/2008 6
Definition: Nonmedical Use of Pharmaceuticals • Based on retrospective chart review • Exceeded prescribed or recommended dose • Used drugs prescribed for another • Malicious poisoning • Substance abuse • Excludes drug-related suicide attempts • Includes suicide ideation, plan, gesture 8
*Significant change, 2004 vs. 2007 2005 vs. 2007 Drug-Related ED Visit Rates, 2004-2007 No significant change 2006 vs. 2007 Source: National estimates from DAWN, 2004-2007 9
Oxycodone Controlled and Immediate Release 10
CI upper bound CI lower bound Estimate Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 * Single- & multi-ingredient formulations Source: National estimates from DAWN, 2007 11
CI upper bound CI lower bound Estimate Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 * Single- & multi-ingredient formulations Source: National estimates from DAWN, 2007 12
Controlled release (CR) OxyContin (99%) Alternate terms: Generic OxyContin Teva OxyContin Impax OxyContin Oxycodone CR Oxycodone ER Oxycodone SR Immediate release (IR) acetaminophen-oxy e.g., Percocet (92%) aspirin-oxy e.g., Percodan ibuprofen-oxy e.g., Combunox oxycodone e.g., Roxicodone Classification of Oxycodone Reports 13
Unknown release type (UK) Oxycodone (95%) alternate terms: Free oxycodone M-Oxy Oxycodone hydrochloride Oxycodone metabolites Classification of Oxycodone Reports (cont'd) 14
CI upper bound CI lower bound Estimate Nonmedical Use of Pharmaceuticals, Oxycodone, by Release Type, 2004-2007 Controlled Immediate Unknown Source: National estimates from DAWN, 2004-2007 15
*Significant change, 2004 vs. 2007 2005 vs. 2007 Oxycodone, CR vs. IR – All Visits No significant change 2006 vs. 2007 2007 2006 2005 2004 Source: DAWN estimates for the U.S., 2004-2007 16
*Significant change, 2004 vs. 2007 2005 vs. 2007 Oxycodone, CR vs. IR – Medical Use No Significant change 2006 vs. 2007 2007 2006 2005 2004 Source: DAWN estimates for the U.S., 2004-2007 17
*Significant change, 2004 vs. 2007 2005 vs. 2007 Oxycodone, CR vs. IR – Nonmedical Use No significant change 2006 vs. 2007 2007 2006 2005 2004 Source: DAWN estimates for the U.S., 2004-2007 18
Oxycodone, CR vs. IR Nonmedical use Medical use % of visits Source: DAWN estimates for the U.S., 2004-2007 19
Hydrocodone Oxycodone: UK IR ER Nonmedical Use: Hydrocodone and Oxycodone by Release Type, 2004-2007 Source: DAWN estimates for the U.S., 2004-2006 20
Nonmedical Use: All Opiates/Opioids, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 21
Nonmedical Use: All Hydrocodone, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 22
Nonmedical Use: All Oxycodone, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 23
Nonmedical Use: Oxycodone CR,ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 24
Nonmedical Use: Oxycodone IR,ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 25
Nonmedical Use: Oxycodone UK,ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 26
Nonmedical Use: Disposition from ED,Oxycodone by Release Type, 2007 % of ED visits No evidence of follow-up care Some follow-up Controlled Immediate Unknown Source: DAWN estimates for the U.S., 2007 27
1 drug Nonmedical Use: Number of Drugs,Oxycodone by Release Type, 2007 % of ED visits Multiple drugs Controlled Immediate Unknown Source: DAWN estimates for the U.S., 2007 28
Nonmedical Use ED Visits: Conclusions • Opioid analgesics nearing 287,000 visits • ¼ Oxycodone ¼ Hydrocodone • in immediate and unknown release types • Highest visit rates in patients aged 21-54 • Majority of patients treated and released • Polydrug use was higher for immediate versus controlled release 29
Morphine Controlled and Immediate Release 30
CI upper bound CI lower bound Estimate Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 * Single- & multi-ingredient formulations Source: National estimates from DAWN, 2007 31
Controlled release (CR) MS Contin (71%) Alternate terms: Avinza Kadian Morphine Sulfate SR Oramorph SR Morphine Extended Release Morphine Patches Immediate release (IR) Morphine Sulfate Morphine Pill Morphine IR Morphine Rapi-Ject Roxanol Morphelan Classification of Morphine Reports 32
CI upper bound CI lower bound Estimate Nonmedical Use of Pharmaceuticals, Morphine, by Release Type, 2004-2007 Immediate Controlled Source: National estimates from DAWN, 2004-2007 33
*Significant change, 2004 vs. 2007 2005 vs. 2007 Morphine, CR vs. IR – All Visits No significant change 2006 vs. 2007 2007 2006 2005 2004 Source: DAWN estimates for the U.S., 2004-2007 34
*Significant change, 2004 vs. 2007 2005 vs. 2007 Morphine, CR vs. IR – Medical Use No Significant change 2006 vs. 2007 Source: DAWN estimates for the U.S., 2004-2007 35
*Significant change, 2004 vs. 2007 2005 vs. 2007 Morphine, CR vs. IR – Nonmedical Use No significant change 2006 vs. 2007 Source: DAWN estimates for the U.S., 2004-2007 36
Morphine, CR vs. IR Nonmedical use Medical use % of visits Source: DAWN estimates for the U.S., 2004-2007 37
Hydrocodone Morphine: UK IR CR Nonmedical Use: Hydrocodone and Morphine by Release Type, 2004-2007 Source: DAWN estimates for the U.S., 2004-2006 38
Nonmedical Use: All Morphine, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 39
Nonmedical Use: Morphine CR,ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 40
Nonmedical Use: Morphine IR,ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007 41
Nonmedical Use: Disposition from ED,Morphine by Release Type, 2007 % of ED visits No evidence of follow-up care Some follow-up Controlled Immediate Unknown Source: DAWN estimates for the U.S., 2007 42
1 drug Nonmedical Use: Number of Drugs,Morphine by Release Type, 2007 % of ED visits Multiple drugs Controlled Immediate Unknown Source: DAWN estimates for the U.S., 2007 43
Nonmedical Use ED Visits: Conclusions • Morphine related ED visits nearing 30,000 • Immediate release • Controlled release is similar 2004-2007 • Highest visit rates in patients aged 21-54 • Majority of patients treated and released • Polydrug use is typical 44
Important Considerations:DAWN Depends on ED Medical Records • Link between ED visit and use of drug • Dose levels and source of drug unavailable • Nonspecific drug reports • Opiates/opioids, unspecified (unnamed) • Unknown release-type • Unique names for immediate versus extended release enable better surveillance 45
Acknowledgements • Rong Cai, Statistician 46